Cervical cancer is the fourth most common cancer in women worldwide and the most common gynaecological malignancy. The majority of cervical cancers in developed countries are diagnosed early at stage I and 5-year overall survival (OS) for all stages remains above 73%. However, there is much room for improvement in the treatment of locally advanced cervical cancer (LACC) as outcomes for patients remain quite poor witt the 5-year OS for patients with regional disease at around 55%. Despite improvements in prognosis thanks to the addition of concurrent chemotherapy to radiotherapy (RT) treatment-related toxicity and distant recurrence remain a challenge.
For patients with LACC, the current standard of care includes pelvic external beam radiotherapy (EBRT) with concurrent chemotherapy plus a brachytherapy boost. In recent years, radiation treatment standards have shifted from a two-dimensional approach to an image-guided three-dimensional approach. This takes into account variations in tumour size and position and aims to deliver doses more precisely to clinical targets with an increased sparing of organs at risk. There is still room for improvement in the treatment of Cervical Cancer with radiotherapy. Potential areas of research include the addition of immunotherapy to chemoradiation regimens and moving toward a more personalized approach to treatment with the identification of risk factors and novel biomarkers.
This Research Topic aims to provide updates on radiotherapy in the treatment of Cervical Cancer. We encourage submissions that focus on, but not limited to, the following themes:
- Advances in EBRT
- Advances in Brachytherapy for the Treatment of LACC
- Incorporation of Immunotherapy and Targeted Therapy Into Chemoradiation for Cervical Cancer
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Cervical cancer is the fourth most common cancer in women worldwide and the most common gynaecological malignancy. The majority of cervical cancers in developed countries are diagnosed early at stage I and 5-year overall survival (OS) for all stages remains above 73%. However, there is much room for improvement in the treatment of locally advanced cervical cancer (LACC) as outcomes for patients remain quite poor witt the 5-year OS for patients with regional disease at around 55%. Despite improvements in prognosis thanks to the addition of concurrent chemotherapy to radiotherapy (RT) treatment-related toxicity and distant recurrence remain a challenge.
For patients with LACC, the current standard of care includes pelvic external beam radiotherapy (EBRT) with concurrent chemotherapy plus a brachytherapy boost. In recent years, radiation treatment standards have shifted from a two-dimensional approach to an image-guided three-dimensional approach. This takes into account variations in tumour size and position and aims to deliver doses more precisely to clinical targets with an increased sparing of organs at risk. There is still room for improvement in the treatment of Cervical Cancer with radiotherapy. Potential areas of research include the addition of immunotherapy to chemoradiation regimens and moving toward a more personalized approach to treatment with the identification of risk factors and novel biomarkers.
This Research Topic aims to provide updates on radiotherapy in the treatment of Cervical Cancer. We encourage submissions that focus on, but not limited to, the following themes:
- Advances in EBRT
- Advances in Brachytherapy for the Treatment of LACC
- Incorporation of Immunotherapy and Targeted Therapy Into Chemoradiation for Cervical Cancer
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.